QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laurenzana, E. M. Articles by Owens, S. M. Search for Related Content PubMed PubMed Citation Articles by Laurenzana, E. M. Articles by Owens, S. M.

USE OF ANTI-(+)-METHAMPHETAMINE MONOCLONAL ANTIBODY TO SIGNIFICANTLY ALTER (+)-METHAMPHETAMINE AND (+)-AMPHETAMINE DISPOSITION IN RATS

Department of Pharmacology and Toxicology (E.M.L., K.A.B.-B., A.M.-H., W.B.G., S.M.O.), Department of Anesthesiology (W.B.G.), and Department of Biostatistics (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas

These studies examined the effects of a high-affinity anti-(+)-methamphetamine monoclonal antibody (mAb; K_D = 11 nM) on (+)-methamphetamine [(+)-METH] and (+)-amphetamine [(+)-AMP] serum and tissue disposition and serum protein binding following i.v. (+)-METH administration. Male Sprague-Dawley rats were pretreated with a buffer solution (control rats) or with anti-(+)-METH mAb [equimolar in binding sites to the (+)-METH dose]. The next day, both groups received a 1 mg/kg i.v. (+)-METH dose. At various time points after (+)-METH administration, rats were sacrificed (n = 3 per time point), and serum and tissues were collected. (+)-METH serum protein binding was increased from 5% in controls to 88 to 99% in the mAb-treated rats. The (+)-METH area under the concentration versus time curves from 0 to 4.5 h (AUC₀^{4.5 h}) in mAb-treated rats showed an increase of >6600% for serum and a decrease of >60% for brain, compared with buffer-treated controls. Differential effects of anti-METH mAb on (+)-METH concentrations were observed in other tissues. For example, in the liver, anti-(+)-METH mAb caused significant increases in (+)-METH concentrations. The AUC₀^{4.5 h} for (+)-AMP, a pharmacologically active metabolite, was decreased by 50% in all tissues examined. These data show that pretreatment with an anti-(+)-METH mAb can significantly alter the disposition of (+)-METH and (+)-AMP in rats. Since the mAb has no significant cross-reactivity with (+)-AMP, the data suggest that the mAb reduced (+)-METH metabolic clearance through high-affinity binding to (+)-METH. Finally, rapidly equilibrating tissues, like the brain, appear to be preferentially protected by the mAb.

This article has been cited by other articles:

				E. C. Peterson, M. Gunnell, Y. Che, R. L. Goforth, F. I. Carroll, R. Henry, H. Liu, and S. M. Owens Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 30 - 39. [Abstract] [Full Text] [PDF]

				A. B. Norman, M. R. Tabet, M. K. Norman, W. R. Buesing, A. J. Pesce, and W. J. Ball A Chimeric Human/Murine Anticocaine Monoclonal Antibody Inhibits the Distribution of Cocaine to the Brain in Mice J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 145 - 153. [Abstract] [Full Text] [PDF]

				P. R. Pentel, M. B. Dufek, S. A. Roiko, M. G. LeSage, and D. E. Keyler Differential Effects of Passive Immunization with Nicotine-Specific Antibodies on the Acute and Chronic Distribution of Nicotine to Brain in Rats J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 660 - 666. [Abstract] [Full Text] [PDF]

				D. E. McMillan, W. C. Hardwick, M. Li, M. G. Gunnell, F. I. Carroll, P. Abraham, and S. M. Owens Effects of Murine-Derived Anti-Methamphetamine Monoclonal Antibodies on (+)-Methamphetamine Self-Administration in the Rat J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1248 - 1255. [Abstract] [Full Text] [PDF]